SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs quarterly results beat expectations and its 2027 adjusted EBITDA outlook was raised, driving a sharp rally. Traders are debating whether strong operating momentum could fuel short covering or whether the companys debt and reliance on steel-price forecasts limit the upside.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a sharp selloff across AI and neocloud infrastructure stocks, with traders debating financing risks, data-center spending and whether AI demand will generate returns. Some see an oversold dip and potential rebound or short squeeze, while others warn the bounce may fail and expect further losses.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus oncology pipeline: the pancreatic IMPACT study completed enrollment after multiple expansions, with traders also focused on further glioblastoma and ReSTART data. The community is broadly optimistic about clinical progress, though the studies remain early-stage and expectations for the stock are speculative.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade to Buy has fueled a rebound after a sharp selloff driven by concerns over CoreWeaves debt burden, bond-market stress and ability to finance its expansion. Traders remain divided: bulls see the financing fears as overblown given AI demand, while bears warn that elevated borrowing costs and credit risk could keep pressure on the stock.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as traders await the 80th death event that triggers final analysis of its Phase 3 REGAL trial; the last company-disclosed count was 78, and the threshold has not been confirmed. Some traders view the prolonged wait and upcoming ASH meeting as possible signs of encouraging survival data, while others caution that a blinded trials delay does not establish efficacy and debate whether results could be under an ASH embargo.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

X-energys proposed AEP study of a large Xe-100 plant in Indiana, with Amazon linked to long-term power demand, is drawing attention as shares slide sharply. Traders are split between buying the dip on Amazons backing and nuclear-power demand, and worrying about continued selling pressure and the long path from feasibility work to commercial reactors.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Recent competitor trial news is driving attention, particularly EyePoints failed wet-AMD study and what it may mean for Oculars AXPAXLI program. Traders are split: some worry the setback could deepen skepticism about TKI therapies, while others see reduced competition and argue AXPAXLIs data and durability are distinct.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

Renewed takeover speculation is driving attention, with traders discussing an unconfirmed report that an unnamed West Coast tech company may be evaluating an all-stock deal; many guess Meta, but no offer or buyer has been confirmed. The community is split between expecting a premium bid and viewing the rumor as a short-lived pump, while some focus on PayPals standalone turnaround and upcoming earnings.

Dynex Capital, Inc. is an internally managed mortgage real estate investment trust. It engages in the business of investing in mortgage-backed securities. The company was founded on December 18, 1987 and is headquartered in Glen Allen, VA.

Dynex Capital, Inc.

Dynexs Q3 results are drawing attention after a sharp decline in book value, which traders attribute mainly to wider agency MBS spreads; they also point to earnings available for distribution falling short of the monthly dividend. The debate is whether improving earnings and managements expanded MBS purchases can support a recovery, or whether weak dividend coverage and further book-value erosion signal more downside.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on the Dows direction amid volatile, mixed equity trading, with some traders pointing to relative strength versus tech while others warn of a pullback. Rising Treasury yields, oil and inflation concerns, Fed policy, and Iran-related uncertainty recur as broader market risks, alongside bullish calls for a rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ABUS Stock Surges 10% Today — What’s Driving This Super Rally?

Equity

Arbutus Biopharma said it will repurchase $230 million of its common shares at a purchase price of not less than $5 per share and not more than $5.75 apiece, in cash.


Should Vanguard Russell 2000 Growth Index Fund ETF Shares (VTWG) Be on Your Investing Radar?

APPS Stock Headed For Best Single-Day Gains In Nearly 14 Months — Q1 Beat Has Wall Street Believing That The Growth Is Just Beginning

Shares of Digital Turbine hit a 52-week high on Wednesday after the company reported its first-quarter results earlier in the day.

This Critical Materials Stock Surged Over 150% In A Year – The Firm’s Now Ready To Hit 2026 Production Guidance In Just 6 Months

Energy Fuels expects to produce 1.6 million pounds of finished uranium from January through June 2026 at its 100%-owned White Mesa Mill in Utah.


APPS Stock Soars 53%, On Track For Best Single-Day Gains In 11 Months — Why Did BofA Turn Bullish On Digital Turbine?

Digital Turbine reported earnings per share of $0.16 in Q4 on revenue of $143 million, while Wall Street expected an EPS of $0.09 on revenue of $133 million.

WYFI Stock Tumbles Nearly 10% After Q4 Earnings Miss — What's Wall Street's Take?

Craig-Hallum lowered its price target on the company to $21 from $25, while maintaining a ‘Buy’ rating on the stock, according to Investing.com. 

ATOM Stock Is Falling Today After Atomera Announces Stock Offering At A Deep Discount

The company announced on Monday that it has entered into a definitive agreement to sell 5 million shares of its common stock at an offering price of $5 per share.

Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?

Vanguard Scottsdale Funds - Vanguard Russell 2000 Growth Index ETF

Neutral Sentiment

<ul class="summary-bullets"><li>The company said it will fund the repurchase with cash in hand.</li><li>The offer will likely commence on or about Aug. 24, 2026, and is expected to expire on or about Sept. 29, 2026.</li><li>During the second quarter, Arbutus Biopharma reported revenue of $1.01 million compared to an estimated $0.68 million as per Fiscal.ai data.</li></ul>Shares of Arbutus Biopharma Corporation (ABUS) surged over 10% in pre-market trading on Friday after the firm announced its intent to repurchase up to $230 million of its common shares.Arbutus Biopharma said it will repurchase the common shares at a purchase price of not less than $5 per share and not more than $5.75 per share, in cash, less any applicable withholding taxes and without interest.The company said it will fund the repurchase with cash in hand. The offer will likely commence on or about Aug. 24, 2026, and is expected to expire on or about Sept. 29, 2026.If Friday’s pre-market level holds, the stock will hit its July highs.<h2 class="st-heading-2">International Lawsuits</h2>Last month, the company, along with its exclusive licensee, Genevant Sciences GmbH, a subsidiary of Roivant Sciences (ROIV), announced the filing of three international lawsuits seeking to enforce patents protecting their innovative LNP technology against Pfizer Inc., BioNTech SE and certain of their affiliates.“We, alongside our exclusive licensee Genevant, will continue to vigorously enforce our rights against infringers, including Pfizer and BioNTech,” said Arbutus Biopharma CEO Lindsay Androski.“Our March 2026 settlement with Moderna, and the July 2026 initial payment under that settlement, were critical milestones in establishing for the world what most of the scientific community already knew: Arbutus’ lipid nanoparticle technology inventions opened the doors to an entirely new world of therapeutic treatments using nucleic acids,” she added.<h2 class="st-heading-2">ABUS’ Q2 At A Glance</h2>During the second quarter, Arbutus Biopharma reported revenue of $1.01 million compared to an estimated $0.68 million as per Fiscal.ai data. The firm reported a loss of $0.03 per share compared to an estimated $0.02.Arbutus Biopharma ended the quarter with cash, cash equivalents, and investments in marketable securities of $92.6 million.<h2 class="st-heading-2">What Retail Thinks About ABUS</h2>On Stocktwits, retail sentiment continued to trend in the ‘extremely bullish’ territory amid high message volume.Stocktwits users expect the stock to rise to at least $6.5. It is currently trading close to $5.3, according to the pre-market rate.<stembedurl>https://stocktwits.com/Gugger/message/662506759</stembedurl><stembedurl>https://stocktwits.com/punktdot/message/662504166</stembedurl>The stock has gained nearly 33% in the last year.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-issues-biggest-ever-recall-in-china-here-s-what-the-ev-maker-will-look-to-fix/cZYBMr6RJNn">Tesla Issues Biggest Ever Recall In China – Here’s What The EV Maker Will Look To Fix</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

Arbutus Biopharma said it will repurchase $230 million of its common shares at a purchase price of not less than $5 per share and not more than $5.75 apiece, in cash.

Arbutus Biopharma Corp

Roivant Sciences Ltd

ProShares Ultra Russell2000

Vanguard Russell 2000 Growth ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$247.33
Prev Close	$253.78
Open	$253.93
Dividend Yield	N/A
50-Day Moving Average	$270.32
Beta	N/A
Avg. Volume	22,556.03
PE Ratio	N/A

52-Week High	$289.14
52-Week Low	$218.84
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

VTWG Fundamentals